Bal Pharma Ltd Financials

Bal Pharma Ltd Financial Statement

Bal Pharma Ltd Income Statement

Quarterly

Annual

*All values are in Rs. Cr

Particulars	Jun 2024	Mar 2024	Dec 2023
Revenue	73.94	96.81	81.74
Operating Expense	66.06	84.26	73.96
Net Profit	1.75	6.22	1.26
Net Profit Margin	2.37	6.42	1.54
Earning Per Share	1.11	4.16	0.80
EBIDTA	8.09	10.67	8.03
Effective Tax Rate	6.97	-11.39	8.48

Particulars	Jun 2024
Revenue	73.94
Operating Expense	66.06
Net Profit	1.75
Net Profit Margin	2.37
Earning Per Share	1.11
EBIDTA	8.09
Effective Tax Rate	6.97

Bal Pharma Ltd Profit & Loss

*All values are in Rs. Cr

Standalone

Consolidated

Particulars	Mar 2024	Mar 2023	Mar 2022
Total Revenue Annual	338.54	303.10	280.37
Operating Expenses Annual	306.10	276.80	257.16
Operating Profit Annual	35.79	28.49	29.69
Interest Annual	15.24	12.46	10.40
Depreciation	4.53	5.52	5.77
Net Profit Annual	10.27	6.13	8.58
Tax Annual	1.83	2.42	3.48

Particulars	Mar 2024
Total Revenue Annual	338.54
Operating Expenses Annual	306.10
Operating Profit Annual	35.79
Interest Annual	15.24
Depreciation	4.53
Net Profit Annual	10.27
Tax Annual	1.83

Bal Pharma Ltd Cash Flow

*All values are in Rs. Cr

Standalone

Consolidated

Particulars	Mar 2024	Mar 2023	Mar 2022
Cash Flow at the Beginning	1.23	0.81	0.89
Cash Flow from Operations	28.95	5.38	30.57
Cash Flow from Investing	-18.43	-22.08	-13.43
Cash Flow from Financing	-7.71	17.12	-17.22
Cash Flow at the End	4.04	1.23	0.81

Particulars	Mar 2024
Cash Flow at the Beginning	1.23
Cash Flow from Operations	28.95
Cash Flow from Investing	-18.43
Cash Flow from Financing	-7.71
Cash Flow at the End	4.04

Bal Pharma Ltd Key Ratios

*All values are in Rs. Cr

Standalone

Consolidated

Particulars	Mar 2024	Mar 2023	Mar 2022
PBDIT Margin (%)	10.63	9.44	10.22
PBIT Margin (%)	8.13	6.97	7.64
PBT Margin (%)	7.60	6.42	6.92
Net PROFIT Margin (%)	3.03	2.02	3.06
Return On Networth / Equity (%)	10.19	6.69	9.36
Return On Networth /Employed (%)	11.63	10.08	11.20
Return On Assets (%)	4.34	2.91	4.47
Total Debt / Equity (X)	1.28	1.22	1.21
Asset Turnover Ratio (%)	1.43	1.44	1.46

Particulars	Mar 2024
PBDIT Margin (%)	10.63
PBIT Margin (%)	8.13
PBT Margin (%)	7.60
Net PROFIT Margin (%)	3.03
Return On Networth / Equity (%)	10.19
Return On Networth /Employed (%)	11.63
Return On Assets (%)	4.34
Total Debt / Equity (X)	1.28
Asset Turnover Ratio (%)	1.43

Bal Pharma Ltd Balance Sheet

*All values are in Rs. Cr

Standalone

Consolidated

Particulars	Mar 2024	Mar 2023	Mar 2022
Fixed Assets Annual	64.56	63.07	52.90
Total Current Assets Annual	281.14	269.95	218.20
Non Current Assets Annual	80.16	77.75	71.56
Total Shareholders Funds Annual	105.58	96.03	87.32
Total Assets Annual	361.30	347.70	289.76

Particulars	Mar 2024
Fixed Assets Annual	64.56
Total Current Assets Annual	281.14
Non Current Assets Annual	80.16
Total Shareholders Funds Annual	105.58
Total Assets Annual	361.30

Bal Pharma Ltd Earning Calls

EPS (INR)

Expected

0.65

Reported

0.65

Surprise

0.00%

Jun 2024

EPS beaten by 0.00%

Mar 2024

EPS beaten by 0.00%

Dec 2023

EPS beaten by 7.80%

Dividend Pages

PE Ratio

Get Your FAQs Right

As of Dec 26, 2024, Bal Pharma Ltd has a market capitalization of 144.21 Cr. Value Research classifies it as a Micro-Cap company.

No, Bal Pharma Ltd is not debt-free with a debt-to-equity ratio of 1.27.

In FY 2023 , Bal Pharma Ltd recorded a total revenue of approximately 338.54 Cr marking a significant milestone in the company's financial performance.

Bal Pharma Ltd's Future outlook anticipates robust growth, with forecasted earnings and revenue rising approximately -0.1% and 0.1% annually, respectively..

Bal Pharma Ltd's current PE ratio is 14.04.

Bal Pharma Ltd's ROCE averaged 10.9% from the FY ending March 2022 to 2024, with a median of 11.4%. It peaked at 11.9% in March 2022, reflecting strong capital efficiency over the period..

Bal Pharma Ltd's latest EBIT is Rs. 27.35 Cr, surpassing the average EBIT of Rs. 23.61 Cr over the 5 years..